Retatrutide (GGG tri-agonist)
A triple-incretin compound studied in metabolic research.
Overview
Retatrutide is a synthetic triple agonist that interacts with the GLP-1, GIP, and glucagon receptors. In research literature it is studied in the context of metabolic and energy-regulation pathways. It is an emerging and frequently referenced compound in the triple-incretin research category.
Referenced research ranges
1–12 mg, once weekly — research protocols reference gradual titration across weeks
Reconstitution default
10 mg in 2 mL yields 5 mg/mL; a 2 mg reference dose is 0.4 mL (40 units on a U-100 syringe).
Storage
Store lyophilized vials refrigerated; refrigerate after reconstitution and protect from light.
Considerations
- Interacts with three receptor targets, distinguishing it from single- and dual-incretin compounds.
- Long half-life, so research protocols reference once-weekly administration.
- Reconstituted peptide is temperature-sensitive and light-sensitive.
Log doses, get reminders, and run the calculator in PepSensei.
PepSensei is an educational reference tool only. Nothing in this library is medical advice, and none of it is intended to diagnose, treat, cure, or prevent any condition. All figures — including dose ranges, half-lives, and reconstitution examples — are commonly-cited values drawn from published research literature and are provided strictly for reference and general education in a research context. They are not protocols, recommendations, or instructions. Always consult a licensed medical professional before making any decision related to your health.